369 related articles for article (PubMed ID: 21723797)
1. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.
Gonzales JC; Fink LM; Goodman OB; Symanowski JT; Vogelzang NJ; Ward DC
Clin Genitourin Cancer; 2011 Sep; 9(1):39-45. PubMed ID: 21723797
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
3. Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer.
Khoury JD; Adcock DM; Chan F; Symanowski JT; Tiefenbacher S; Goodman O; Paz L; Ma Y; Ward DC; Vogelzang NJ; Fink LM
Am J Clin Pathol; 2010 Dec; 134(6):964-9. PubMed ID: 21088161
[TBL] [Abstract][Full Text] [Related]
4. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
5. A panel of five circulating microRNAs as potential biomarkers for prostate cancer.
Chen ZH; Zhang GL; Li HR; Luo JD; Li ZX; Chen GM; Yang J
Prostate; 2012 Sep; 72(13):1443-52. PubMed ID: 22298030
[TBL] [Abstract][Full Text] [Related]
6. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases.
Thiounn N; Saporta F; Flam TA; Pages F; Zerbib M; Vieillefond A; Martin E; Debré B; Chevillard S
Urology; 1997 Aug; 50(2):245-50. PubMed ID: 9255296
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
8. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.
Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):631-4. PubMed ID: 9681533
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
Danila DC; Heller G; Gignac GA; Gonzalez-Espinoza R; Anand A; Tanaka E; Lilja H; Schwartz L; Larson S; Fleisher M; Scher HI
Clin Cancer Res; 2007 Dec; 13(23):7053-8. PubMed ID: 18056182
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
14. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
[TBL] [Abstract][Full Text] [Related]
15. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
[TBL] [Abstract][Full Text] [Related]
16. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
[TBL] [Abstract][Full Text] [Related]
17. [Value of determining prostate specific antigen in follow-up of prostatic cancer].
Sadeh AD; Mukamel E; Galili Y; Nussbaum B; Regev D; Servadio C
Harefuah; 1993 Aug; 125(3-4):69-74, 128. PubMed ID: 7693556
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
Grande M; Carlström K; Rozell BL; Stege R; Pousette A
Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
[TBL] [Abstract][Full Text] [Related]
19. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
[TBL] [Abstract][Full Text] [Related]
20. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
